Current Issue
Volumes and Issues
For Authors
Manuscript Guidelines
Review Process
Conflict of Interest
Copyright
About the Journal
Editorial Board
Aim and Scope
Policy and Ethical Guidelines
Promotion of the Journal
Print-Version Subscription
Publisher and Contact Information
Contact Information
Sign in
ORIGINAL ARTICLE
COCHLEAR INVOLVEMENT IN VITILIGO PATIENTS
1
Audio-Vestibular Unit, Otorhinolaryngology Department, Kasr Al-Ainy Faculty of Medicine, Cairo University, Egypt
2
Department of Dertmatology,, Kasr-Al-Ainy Faculty of Medicine, Cairo University, Egypt, Egypt
A - Research concept and design; B - Collection and/or assembly of data; C - Data analysis and interpretation; D - Writing the article; E - Critical revision of the article; F - Final approval of article;
Submission date: 2020-05-06
Final revision date: 2020-09-30
Acceptance date: 2020-12-03
Publication date: 2020-12-31
Corresponding author
Abeir Osman Dabbous
Audio-Vestibular Unit, Otorhinolaryngology Department, Kasr Al-Ainy Faculty of Medicine, Cairo University, Cairo University, 12211, Giza, Cairo,, Egypt
Audio-Vestibular Unit, Otorhinolaryngology Department, Kasr Al-Ainy Faculty of Medicine, Cairo University, Cairo University, 12211, Giza, Cairo,, Egypt
J Hear Sci 2020;10(4):69-82
KEYWORDS
TOPICS
ABSTRACT
Background:
Vitiligo is a common chronic disease of pigmentation, which may be accompanied by audiological abnormalities.
Material and methods:
The aim of this study was to assess vitiligo patients in terms of hearing thresholds using conventional pure tone audiometry (0.25 to 8 kHz), high frequency pure tone audiometry (10 and 12.5 kHz), as well as Transient Evoked Otoacoustic Emissions (TEOAEs). We correlated the audiometric findings with vitiligo duration and severity. The study included 75 subjects with a mean age of 29.7 ± 8.6 years. There were 50 vitiligo patients and 25 age and gender matched healthy controls who had never had any audiological condition or exposed to excessive noise.
Results:
Only 24% of vitiligo patients had high frequency sensorineural hearing loss (SNHL) using conventional audiometry and the majority (76%) had bilaterally normal hearing. The majority (90%) of vitiligo patients had SNHL in extended high frequency audiometry. There was a statistically significant difference between the cases and controls regarding TEOAE SNR at 5 kHz, and nearly half of the normal hearers had an abnormal TEOAE. Vitiligo patients were found to have subclinical inner ear dysfunction compared with the controls. There was a statistically significant correlation between PTA and age of the patients but not with vitiligo duration or severity.
Conclusions:
The audiometric findings of the vitiligo group and the statistically significant differences from the control group suggest a subclinical involvement of the cochlea, probably related to the vitiligo condition, but not affected by vitiligo duration or severity. We therefore recommend the use of extended high frequency audiometry and otoacoustic emission tests for early detection of inner ear involvement in vitiligo.
Vitiligo is a common chronic disease of pigmentation, which may be accompanied by audiological abnormalities.
Material and methods:
The aim of this study was to assess vitiligo patients in terms of hearing thresholds using conventional pure tone audiometry (0.25 to 8 kHz), high frequency pure tone audiometry (10 and 12.5 kHz), as well as Transient Evoked Otoacoustic Emissions (TEOAEs). We correlated the audiometric findings with vitiligo duration and severity. The study included 75 subjects with a mean age of 29.7 ± 8.6 years. There were 50 vitiligo patients and 25 age and gender matched healthy controls who had never had any audiological condition or exposed to excessive noise.
Results:
Only 24% of vitiligo patients had high frequency sensorineural hearing loss (SNHL) using conventional audiometry and the majority (76%) had bilaterally normal hearing. The majority (90%) of vitiligo patients had SNHL in extended high frequency audiometry. There was a statistically significant difference between the cases and controls regarding TEOAE SNR at 5 kHz, and nearly half of the normal hearers had an abnormal TEOAE. Vitiligo patients were found to have subclinical inner ear dysfunction compared with the controls. There was a statistically significant correlation between PTA and age of the patients but not with vitiligo duration or severity.
Conclusions:
The audiometric findings of the vitiligo group and the statistically significant differences from the control group suggest a subclinical involvement of the cochlea, probably related to the vitiligo condition, but not affected by vitiligo duration or severity. We therefore recommend the use of extended high frequency audiometry and otoacoustic emission tests for early detection of inner ear involvement in vitiligo.
REFERENCES (43)
1.
Iannella G, Greco A, Didona D, Didona B, Granata G, Manno A, Pasquariello B, Magliul G. Vitiligo: pathogenesis, clinical variants and treatment approaches. Autoimmunity Reviews, 2016; 15(4): 335–43.
2.
Fleissig E, Gross M, Ophir I, Elidan J, Bdolah-Abram T, Ingber A. Risk of sensorineural hearing loss in patients with vitiligo. Audiol Neurootol, 2013; 18: 240–6.
3.
Anbar TS, El-Badry MM, McGrath JA, Abdel-Azim ES. Most individuals with either segmental or non-segmental vitiligo display evidence of bilateral cochlear dysfunction. Br J Dermatol, 2015; 172(2): 406–11.
4.
Dahir AM, Thomsen SF. Comorbidities in vitiligo: comprehensive review. Int J Dermatol, 2018; 57(10): 1157–64.
5.
McGinness J, Corry P, Proctor P. Amorphous semiconductor switching in melanins. Science, 1974; 183(4127): 853–5.
6.
Tachibana M. Cochlear melanocytes and MITF signaling. J Investig Dermatol Symp Proc, 2001; 6(1): 95–8.
7.
Akay BN, Bozkir M, Anadolu Y, Gullu S. Epidemiology of vitiligo, associated autoimmune diseases and audiological abnormalities: Ankara study of 80 patients in Turkey. J Eur Acad Dermatol Venereol, 2010; 24: 1144–50.
8.
Aslan S, Serarslan G, Teksoz E, Dagli S. Audiological and transient evoked otoacoustic emission findings in patients with vitiligo. Otolaryngol Head Neck Surg, 2010; 142: 409–14.
9.
Aydogan K, Turan OF, Onart S, Karadogan SK, Tunali S. Audiological abnormalities in patients with vitiligo. Clin Exp Dermatol, 2006; 31: 110–13.
10.
Mahdi P, Rouzbahani M, Amali A, Rezaii Khiabanlu S, Kamali M. Audiological manifestations in vitiligo patients. Iran J Otorhinolaryngol, 2012; 24: 35–40.
11.
Tosti A, Bardazzi F, Tosti G, Monti L. Audiologic abnormalities in cases of vitiligo. J Am Acad Dermatol, 1987; 17: 230–3.
12.
Nikiforidis GC, Tsambaos DG, Karamitsos DS et al. Abnormalities of the auditory brainstem response in vitiligo. Scand Audiol, 1993; 22: 97–100.
13.
Ozuer MZ, Sahiner T, Aktan S et al. Auditory evoked potentials in vitiligo patients. Scand Audiol, 1998; 27: 255–8.
14.
Ardic FN, Aktan S, Kara CO, Sanli B. High-frequency hearing and reflex latency in patients with pigment disorder. Am J Otol, 1998; 19: 365–9.
15.
Sharma L, Bhawan R, Jain RK. Hypoacusis in vitiligo. Indian J Dermatol Venereol Leprol, 2004; 70: 162–4.
16.
Steel KP, Barkway C. Another role for melanocytes: their importance for normal stria vascularis development in mammalian inner ear. Development, 1989; 107: 453–63.
17.
Tachibana M. Sound needs sound melanocytes to be heard. Pigment Cell Res, 1999; 12: 344–54.
18.
Ortonne JP, Bahadoran P et al. Hypomelanoses and hypermelanosis. In: Fitzpatrick’s Dermatology in General Medicine (Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, eds), 6th edn. New York: McGraw-Hill, 2003: 836–81.
19.
Kemp, DT. Otoacoustic emissions, their origin in cochlear function, and use. Br Med Bull, 2002; 63: 223–41.
20.
Fabijańska A, Smurzyński J, Hatzopoulos S, et al. The relationship between distortion product otoacoustic emissions and extended high-frequency audiometry in tinnitus patients. Part 1: normally hearing patients with unilateral tinnitus. Med Sci Monitor, 2012; Dec; 18(12): 765–70.
21.
Carvalho S, Mom T, Gilain L, Ayan P. Frequency specificity of distortion-product otoacoustic emissions produced by high-level tones despite inefficient cochlear electromechanical feedback. J Acoust Soc Am, 2004; 116(3): 1639–48.
22.
Hamzavi I, Jain H, McLean D, Shapiro J, Zeng H, Lui H. Parametric modeling of narrowband UV-B phototherapy for vitiligo, using a novel quantitative tool: The Vitiligo Area Scoring Index. Arch Dermatol, 2004; 140: 677–83.
23.
Feily A. Vitiligo Extent Tensity Index (VETI) score: a new definition, assessment and treatment evaluation criteria in vitiligo. Dermatol Pract Concept, 2014; 4(4): 18.
24.
Dicle O. Assessment methods in vitiligo. J Pigmentary Disorders; 2015; 2(1): 1–2.
25.
Bhor U, Pande S. Scoring systems in dermatology. Indian J Dermatol Venereol Leprol, 2006; 72: 315–21.
26.
Clark J. Uses and abuses of hearing loss classification. ASHA, 1981; 23(7): 493–500.
27.
Kemp, D. Otoacoustic emissions, travelling waves and cochlear mechanisms. Hear Res, 1986; 22: 95–104.
28.
Dawoud EAE, Ismail EI, Eltoukhy SA, El-Sharabasy AE. Assessment of auditory and vestibular functions in vitiligo patients. J Otol, 2017; 12(3):143–9.
29.
Sahrifian MR, Maleki M, Honarvar H. The correlation between vitiligo and hearing loss. Iran J Otorhinolaryngol, 2006; 17: 3–8.
30.
Karsai L, Bergman M, Choo Y. Hearing in ethnically different longshore men. Arch Otolaryngol, 1972; 96: 499.
31.
Gill SS, Salt AN. Quantitative differences in endolymphatic calcium and endocochlear potential between pigmented and albino guinea pigs. Hear Res, 1997;113(1): 191–7.
32.
Gopal KV, Rama Rao GR, Kumar YH, et al. Vitiligo: a part of a systemic autoimmune process. Indian J Dermatol Venereol Leprol, 2007; 73: 162–5.
33.
Al-Mutairi N, Al-Sebeih KH. Late onset vitiligo and audiological abnormalities: is there any association? Indian J Dermatol Venereol Leprol, 2011; 77: 571–6.
34.
El Gohary ME, Behairy RA, Awida AM. Effect of vitiligo on the cochlea. Egypt J Otolaryngol, 2019; 35: 6–11.
35.
Hong CK, Lee MH, Jeong KH, Cha CI, Yeo SG. Clinical analysis of hearing levels in vitiligo patients. Eur J Dermatol, 2009; 19: 50–6.
36.
LaFerriere KA, Kaufman-Arenberg I, Hawkin JE, Johnsson LG. Melanocytes of the vestibular labyrinth and their relationship to microvasculature. Ann Otol Laryngol, 1974; 83: 685–94.
37.
Escalante-Ugalde C, Poblano A, Montes de Oca E, Lagunes R, Saul A. No evidence of hearing loss in patients with vitiligo. Arch Dermatol, 1991; 127: 1240.
38.
Shalaby MES, El-Zarea GA, Nassar AL. Auditory function in vitiligo patients. Egypt Dermatol Online J, 2006; 2(1): 7.
39.
Angrisani RM, Azevedo MF, Pereira LD, Lopes C, Garcia MV. A study on otoacoustic emissions and suppression effects in patients with vitiligo. Braz J Otorhinolaryngol, 2009; 75(1): 111–5.
40.
de Jong MA, Adelman C, Gross M. Hearing loss in vitiligo: current concepts and review. Eur Arch Otorhinolaryngol, 2017; 274: 2367–72.
41.
Arya R, Munjal SK, Panda NK, Prasad D. Audiological and electrophysiological changes in patients with vitiligo. Indian J Otolaryngol Head Neck Surg, 2016; 68(4): 417–23.
42.
Schrott A, Spoendlin H. Pigment anomaly associated inner ear deafness. Acta Otolaryngol (Stockh), 1987; 103: 451–7.
43.
Bassiouny A, Farid S, El Khousht M. Hearing abnormalities in vitiligo. Egypt J Otolaryngol, 1998; 15.1; 51–60.
Share
RELATED ARTICLE
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
